Lenalidomide receives FDA approval for expanded use in multiple myeloma

the ONA take:

Celgene received FDA approval to expand the indications for lenaliodomide (Revlimid) to include treatment of newly diagnosed multiple myeloma.

The drug was previously approved only for patients who had received at least one previous therapy. Although, many physicians have been prescribing the drug for patients with new diagnoses on an off-label basis, the company was not allowed to promote its use for these patients.

European physicians are not allowed to prescribe off-label, but Celgene expects European regulators to approve the drug for use in newly diagnosed cases in the next few weeks. In the United States, approximately 88,499 people are living with multiple myeloma; in Europe, approximately 93,600 people are living with the disease. 

Lenalidomide is also approved for the treatment of mantle cell lymphoma when the disease has progressed after two prior therapies, and for myelodysplastic syndromes in both the United States and Europe.

Eribulin effective for earlier treatment of metastatic breast cancer
Celgene received FDA approval to expand the indications for lenaliodomide (Revlimid) to include treatment of newly diagnosed multiple myeloma.
Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an "off-label" basis, but the company had not been allowed to promote its use in this population.
READ FULL ARTICLE From Reuters
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs